A forum for researchers, students and applicants in the field of cyclodextrin technology
Insulin is the most effective drug in the treatment of diabetes mellitus. At present, subcutaneous injection is still the common
Potato peels (PP) are a major agri-food side-stream originating from potato processing, but to date, their green valorization as a
This chapter tells how the cyclodextrin production was started in Hungary in seventies and eighties of the 20st century, at
Niemann-Pick Disease Type C (NPC) is a severe neurovisceral disorder that is pathophysiologically characterized by intracellular transport abnormalities leading to
2-hydroxypropyl-β-cyclodextrin (HPβCD), a cholesterol chelator used to treat Niemann-Pick C1 (NPC1) lysosomal storage disease, causes hearing loss in mammals by
Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio‐delivery and biodistribution of medicines, announced encouraging headline results
CycloLab’s submission to InnoCentive Challenge 9934291 – New Technologies to Prevent the Transmission of Coronavirus led to a favorable evaluation.
Obesity has become a worldwide health crisis and is associated with a plethora of comorbidities. Cardiovascular disease (CVD) and type
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
